fewer women were screened for cervical cancer between 2019 and 20232
of women are not up to date with their screening
of women diagnosed with cervical cancer had not received appropriate screening in the 5 years prior to their diagnosis 4
In many cases, noncompliance with screening guidelines can be attributed to lack of knowledge or access to appropriate care. There are also some women who delay testing because of the invasive nature of speculum-based specimen collection.
These may include:
• American College of Obstetrics and Gynecology8
• US Preventive Services Task Force9
• American Cancer Society10
Learn more about our screening solutions.
Our comprehensive array of screening options is designed to reduce barriers and empower you to tailor testing approaches to meet the unique needs of each patient.
HPV testing is recognized as providing the most clinically useful results for detecting cervical cancer risk in its earliest stages when treatment is likely to have the greatest impact.
We provide robust cytology testing and reporting to meet your cervical cancer screening needs.
Co-testing with Pap and HPV together helps identify more cases of cancer and precancer than either test alone. In a recent Quest Diagnostics Health Trends® retrospective, longitudinal study:13
Co-testing versus HPV alone
Data <12 months of cancer diagnosis
The Aptima mRNA HPV assay targets E6/E7 mRNA and identifies high risk infections that are both present and active, reducing the need for unnecessary patient call backs and overtreatment.
HPV types 16, 18, and 45 are associated with up to 80% of squamous cell carcinomas and up to 92% of HPV-related cervical adenocarcinomas.
Guidelines from ACOG, USPSTF,* and ASCCP continue to endorse co-testing* as a Grade A–level screening option in women ages 30-65.8,10,12
*Endorses the 2018 USPSTF guidelines.
Co-testing versus Pap alone
Data <12 months of precancer diagnosis
Smart Codes help you order the combination of an image-guided Pap, HPV test, and sexually transmitted infection (STI) testing appropriate for your patient's age and risk factors.8,9,12
Components of panels can be ordered separately: ThinPrep Image-guided Pap (test code 58315); SurePath™ Imaging Pap (test code 18810); HPV mRNAE6/E7 (test code 90887); HPV Genotypes 16, 18/45 (test code 91826); Trichomonas vaginalis RNA, Qualitative, TMA, Pap Vial (test code 90521); Chlamydia trachomatis RNA, TMA, Urogenital (test code 11361); Neisseria gonorrhoeae RNA, TMA, Urogenital (test code 11362); Chlamydia/ Neisseria gonorrhoeae RNA, TMA, Urogenital (test code 11363).
Test codes may vary by location. Please contact your local laboratory for more information.
With primary HPV screening, the hrHPV test is used as the primary method to assess cervical cancer risk, with the Pap test reserved for follow-up when the hrHPV test identifies potential concerns. With traditional co-testing, both tests are performed simultaneously.
The USPSTF recommends primary HPV screening in women 30-65 years old9
For some patients, self-collection provides a more discreet screening option. To meet the need for more flexibility, patients in any medical setting can privately collect the specimen using a vaginal swab.
Quest is committed to supporting you in providing the necessary testing for your patients.
Test codes may vary by location. Please contact your local laboratory for more information.
References:
Age-based Smart Codes make it easy to order cervical cancer screening based on guidelines.
Colorectal cancer that is caught in the early stages has a 5-year survival rate of over 90%. InSure® ONE™ makes it easy with at-home testing.
With rates of sexually transmitted infections (STIs) on the rise, assessing women who may be high-risk is more important than ever.
Contact us to receive additional information on our lab tests, services, and coverage
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.
